丹麦生物技术公司Genmab和美国制药商艾伯维周一表示，他们针对新诊断出某种淋巴瘤患者的联合治疗在后期研究中降低了疾病进展或死亡的风险。
Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.